RU2013151301A - Способы и композиции для модулирования экспрессии генов с использованием компонентов, которые обладают способностью к самосборке в клетках и обусловливают рнкi-активность - Google Patents
Способы и композиции для модулирования экспрессии генов с использованием компонентов, которые обладают способностью к самосборке в клетках и обусловливают рнкi-активность Download PDFInfo
- Publication number
- RU2013151301A RU2013151301A RU2013151301/10A RU2013151301A RU2013151301A RU 2013151301 A RU2013151301 A RU 2013151301A RU 2013151301/10 A RU2013151301/10 A RU 2013151301/10A RU 2013151301 A RU2013151301 A RU 2013151301A RU 2013151301 A RU2013151301 A RU 2013151301A
- Authority
- RU
- Russia
- Prior art keywords
- chain
- specified
- target
- chains
- complementary
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 16
- 238000000034 method Methods 0.000 title claims 21
- 108090000623 proteins and genes Proteins 0.000 title claims 2
- 238000001338 self-assembly Methods 0.000 title 1
- 239000002777 nucleoside Substances 0.000 claims abstract 46
- 230000000295 complement effect Effects 0.000 claims abstract 33
- 239000003814 drug Substances 0.000 claims abstract 28
- 125000003835 nucleoside group Chemical group 0.000 claims abstract 28
- 229940079593 drug Drugs 0.000 claims abstract 27
- 230000004048 modification Effects 0.000 claims abstract 26
- 238000012986 modification Methods 0.000 claims abstract 26
- 238000001727 in vivo Methods 0.000 claims abstract 22
- 229920002477 rna polymer Polymers 0.000 claims abstract 20
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract 17
- 230000000694 effects Effects 0.000 claims abstract 13
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 12
- 239000002773 nucleotide Substances 0.000 claims abstract 11
- 125000003729 nucleotide group Chemical group 0.000 claims abstract 11
- 230000001965 increasing effect Effects 0.000 claims abstract 10
- 238000002360 preparation method Methods 0.000 claims abstract 10
- 101710163270 Nuclease Proteins 0.000 claims abstract 9
- 108020004707 nucleic acids Proteins 0.000 claims abstract 5
- 102000039446 nucleic acids Human genes 0.000 claims abstract 5
- 229940002612 prodrug Drugs 0.000 claims abstract 5
- 239000000651 prodrug Substances 0.000 claims abstract 5
- 230000008859 change Effects 0.000 claims abstract 3
- 230000002401 inhibitory effect Effects 0.000 claims abstract 3
- 230000000692 anti-sense effect Effects 0.000 claims 38
- 210000004027 cell Anatomy 0.000 claims 18
- 108020004999 messenger RNA Proteins 0.000 claims 13
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 12
- 238000000338 in vitro Methods 0.000 claims 11
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 10
- 239000002243 precursor Substances 0.000 claims 10
- 108091070501 miRNA Proteins 0.000 claims 9
- 239000002679 microRNA Substances 0.000 claims 9
- 210000001519 tissue Anatomy 0.000 claims 9
- 210000000130 stem cell Anatomy 0.000 claims 8
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 7
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims 7
- 239000002585 base Substances 0.000 claims 7
- -1 cyclohexenyl nucleoside Chemical class 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 6
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 5
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims 5
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 238000004891 communication Methods 0.000 claims 5
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- 239000002342 ribonucleoside Substances 0.000 claims 5
- SXUXMRMBWZCMEN-UHFFFAOYSA-N 2'-O-methyl uridine Natural products COC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-UHFFFAOYSA-N 0.000 claims 4
- SXUXMRMBWZCMEN-ZOQUXTDFSA-N 2'-O-methyluridine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-ZOQUXTDFSA-N 0.000 claims 4
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 4
- YVXABFKQJVTPTI-RWEMILLDSA-N N-(2-aminoethyl)-2-[(2S,4S,5R)-2-(2,4-dioxopyrimidin-1-yl)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]acetamide Chemical compound NCCNC(=O)C[C@@]1(C[C@H](O)[C@@H](CO)O1)N1C(=O)NC(=O)C=C1 YVXABFKQJVTPTI-RWEMILLDSA-N 0.000 claims 4
- CYMGRHYUUDGHDJ-MXIGGHDUSA-N NCCC1[C@@](O[C@@H]([C@H]1O)CO)(N1C(=O)NC(=O)C(C)=C1)CC(NCCN)=O Chemical compound NCCC1[C@@](O[C@@H]([C@H]1O)CO)(N1C(=O)NC(=O)C(C)=C1)CC(NCCN)=O CYMGRHYUUDGHDJ-MXIGGHDUSA-N 0.000 claims 4
- 108091081021 Sense strand Proteins 0.000 claims 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 4
- SJEHRUIZCVJWGX-UHFFFAOYSA-N [1-(hydroxymethyl)-2h-pyridin-3-yl]methanol Chemical compound OCN1CC(CO)=CC=C1 SJEHRUIZCVJWGX-UHFFFAOYSA-N 0.000 claims 4
- XMUZQOKACOLCSS-UHFFFAOYSA-N [2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=CC=C1CO XMUZQOKACOLCSS-UHFFFAOYSA-N 0.000 claims 4
- YWMLORGQOFONNT-UHFFFAOYSA-N [3-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=CC(CO)=C1 YWMLORGQOFONNT-UHFFFAOYSA-N 0.000 claims 4
- 150000001408 amides Chemical class 0.000 claims 4
- 125000005841 biaryl group Chemical group 0.000 claims 4
- 239000004202 carbamide Substances 0.000 claims 4
- 230000030833 cell death Effects 0.000 claims 4
- 239000005549 deoxyribonucleoside Substances 0.000 claims 4
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 claims 4
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 3
- 206010070834 Sensitisation Diseases 0.000 claims 3
- 231100000433 cytotoxic Toxicity 0.000 claims 3
- 230000001472 cytotoxic effect Effects 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 230000003211 malignant effect Effects 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 230000008313 sensitization Effects 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 206010014561 Emphysema Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 claims 2
- 230000022131 cell cycle Effects 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 150000004713 phosphodiesters Chemical class 0.000 claims 2
- 150000003290 ribose derivatives Chemical class 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 1
- 206010065553 Bone marrow failure Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 201000005488 Capillary Leak Syndrome Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010062759 Congenital dyskeratosis Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012305 Demyelination Diseases 0.000 claims 1
- 102000008857 Ferritin Human genes 0.000 claims 1
- 108050000784 Ferritin Proteins 0.000 claims 1
- 238000008416 Ferritin Methods 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020649 Hyperkeratosis Diseases 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010022491 Insulin resistant diabetes Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000034486 Multi-organ failure Diseases 0.000 claims 1
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 108091028664 Ribonucleotide Proteins 0.000 claims 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims 1
- 208000031932 Systemic capillary leak syndrome Diseases 0.000 claims 1
- 108010017842 Telomerase Proteins 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 150000001336 alkenes Chemical class 0.000 claims 1
- 230000003941 amyloidogenesis Effects 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 229910000085 borane Inorganic materials 0.000 claims 1
- 230000003925 brain function Effects 0.000 claims 1
- 238000009395 breeding Methods 0.000 claims 1
- 230000001488 breeding effect Effects 0.000 claims 1
- 230000032677 cell aging Effects 0.000 claims 1
- 230000025084 cell cycle arrest Effects 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 150000001875 compounds Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 claims 1
- 229910003460 diamond Inorganic materials 0.000 claims 1
- 239000010432 diamond Substances 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 claims 1
- 210000001671 embryonic stem cell Anatomy 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 230000030279 gene silencing Effects 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 208000000069 hyperpigmentation Diseases 0.000 claims 1
- 230000003810 hyperpigmentation Effects 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000006882 induction of apoptosis Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate Chemical compound [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 claims 1
- 230000002132 lysosomal effect Effects 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 210000000578 peripheral nerve Anatomy 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 208000003619 porokeratosis Diseases 0.000 claims 1
- 230000006659 positive regulation of apoptotic process Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 210000000512 proximal kidney tubule Anatomy 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
- 238000011160 research Methods 0.000 claims 1
- 230000000284 resting effect Effects 0.000 claims 1
- 239000002336 ribonucleotide Substances 0.000 claims 1
- 125000002652 ribonucleotide group Chemical group 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000009919 sequestration Effects 0.000 claims 1
- 230000002269 spontaneous effect Effects 0.000 claims 1
- 230000035882 stress Effects 0.000 claims 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical group NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- 150000003457 sulfones Chemical class 0.000 claims 1
- 150000003462 sulfoxides Chemical class 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 238000013519 translation Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/52—Methods for regulating/modulating their activity modulating the physical stability, e.g. GC-content
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161477283P | 2011-04-20 | 2011-04-20 | |
| US201161477291P | 2011-04-20 | 2011-04-20 | |
| US61/477,291 | 2011-04-20 | ||
| US61/477,283 | 2011-04-20 | ||
| US201161477875P | 2011-04-21 | 2011-04-21 | |
| US61/477,875 | 2011-04-21 | ||
| PCT/US2012/034595 WO2012145729A2 (en) | 2011-04-20 | 2012-04-20 | Methods and compositions for modulating gene expression using components that self assemble in cells and produce rnai activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013151301A true RU2013151301A (ru) | 2015-05-27 |
Family
ID=47042197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013151301/10A RU2013151301A (ru) | 2011-04-20 | 2012-04-20 | Способы и композиции для модулирования экспрессии генов с использованием компонентов, которые обладают способностью к самосборке в клетках и обусловливают рнкi-активность |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20150038549A1 (https=) |
| EP (1) | EP2699271A4 (https=) |
| JP (1) | JP2014519806A (https=) |
| CN (1) | CN104271740A (https=) |
| AU (1) | AU2012245188A1 (https=) |
| BR (1) | BR112013027070A2 (https=) |
| CA (1) | CA2871089A1 (https=) |
| IL (1) | IL228951A0 (https=) |
| RU (1) | RU2013151301A (https=) |
| WO (1) | WO2012145729A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2697249T3 (es) * | 2013-03-11 | 2019-01-22 | Fond Telethon | miR-204 y miR-211 y usos de los mismos |
| CN105264092B (zh) * | 2013-03-15 | 2019-02-22 | 得克萨斯州大学系统董事会 | 用于诊断和疗法的外来体中的miRNA生物发生 |
| WO2015106128A2 (en) * | 2014-01-09 | 2015-07-16 | Alnylam Pharmaceuticals, Inc. | MODIFIED RNAi AGENTS |
| WO2015168661A1 (en) * | 2014-05-01 | 2015-11-05 | Smith Larry J | METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT |
| PT3166607T (pt) | 2014-07-11 | 2022-12-07 | Gilead Sciences Inc | Moduladores de receptores de tipo toll para o tratamento do vih |
| SG11201701402QA (en) * | 2014-08-27 | 2017-03-30 | Peptimed Inc | Anti-tumor compositions and methods |
| CN108135921B (zh) | 2015-07-22 | 2023-10-17 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| HK1257270A1 (zh) | 2015-09-15 | 2019-10-18 | Gilead Sciences, Inc. | 用於治疗hiv的toll样受体(tlr)调节剂 |
| EP4065716A4 (en) * | 2019-11-26 | 2024-06-12 | City of Hope | MICRORNA AS A THERAPEUTIC |
| US20250297258A1 (en) * | 2021-07-07 | 2025-09-25 | Ractigen Therapeutics | Oligonucleotide-based delivery vehicle for oligonucleotides agents and methods of use thereof |
| WO2024098061A2 (en) | 2022-11-04 | 2024-05-10 | Genkardia Inc. | Oligonucleotide-based therapeutics targeting cyclin d2 for the treatment of heart failure |
| WO2024108217A1 (en) | 2022-11-18 | 2024-05-23 | Genkardia Inc. | Methods and compositions for preventing, treating, or reversing cardiac diastolic dysfunction |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050119212A1 (en) | 2001-05-18 | 2005-06-02 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA) |
| US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| EP2213737B1 (en) | 2002-02-01 | 2012-11-07 | Life Technologies Corporation | Double-stranded oligonucleotides |
| US20040014957A1 (en) * | 2002-05-24 | 2004-01-22 | Anne Eldrup | Oligonucleotides having modified nucleoside units |
| US6841675B1 (en) | 2002-06-13 | 2005-01-11 | The Regents Of The University Of California | Piperazine-based nucleic acid analogs |
| WO2005042719A2 (en) | 2003-10-30 | 2005-05-12 | The Cbr Institute For Biomedical Research, Inc. | Methods for treating and preventing ischemia-reperfusion injury using rna interfering agents |
| WO2005074966A1 (en) | 2004-02-06 | 2005-08-18 | Adelaide Research & Innovation Pty. Ltd. | A method of modulating cellular uptake and molecules useful for same |
| WO2005079533A2 (en) * | 2004-02-17 | 2005-09-01 | University Of Massachusetts | Methods and compositions for mediating gene silencing |
| US20050260755A1 (en) * | 2004-04-06 | 2005-11-24 | Isis Pharmaceuticals, Inc. | Sequential delivery of oligomeric compounds |
| PL1786472T3 (pl) | 2004-08-10 | 2013-06-28 | Kastle Therapeutics Llc | Antysensowna modulacja ekspresji apolipoproteiny B |
| US7528118B2 (en) | 2004-09-24 | 2009-05-05 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of ApoB and uses thereof |
| AU2005288522B2 (en) | 2004-09-28 | 2012-06-28 | Quark Pharmaceuticals, Inc. | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases |
| CA2587411A1 (en) | 2004-11-17 | 2006-05-26 | Protiva Biotherapeutics, Inc. | Sirna silencing of apolipoprotein b |
| CN101517407A (zh) | 2005-09-07 | 2009-08-26 | 纽约州州立大学研究基金会 | 用于研究动脉粥样硬化损害的动物模型 |
| US7910566B2 (en) | 2006-03-09 | 2011-03-22 | Quark Pharmaceuticals Inc. | Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA |
| EP2023940B1 (en) | 2006-05-05 | 2011-06-22 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of sglt2 |
| ES2874149T3 (es) | 2006-05-11 | 2021-11-04 | Alnylam Pharmaceuticals Inc | Composiciones y métodos para inhibir la expresión del gen PCSK9 |
| WO2008033285A2 (en) | 2006-09-15 | 2008-03-20 | The Trustees Of Culumbia University In The City Of New York | Delivery of double-stranded rna into the central nervous system |
| CN101679979A (zh) | 2007-03-24 | 2010-03-24 | 基酶有限公司 | 施用与人载脂蛋白b互补的反义寡核苷酸 |
| AR066984A1 (es) | 2007-06-15 | 2009-09-23 | Novartis Ag | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) |
| WO2010105096A2 (en) * | 2009-03-11 | 2010-09-16 | University Of Massachusetts | Modulation of human cytomegalovirus replication by micro-rna 132 (mir132), micro-rna 145 (mir145) and micro-rna 212 (mir212) |
| US20130079382A1 (en) * | 2009-10-12 | 2013-03-28 | Larry J. Smith | Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro |
-
2012
- 2012-04-20 RU RU2013151301/10A patent/RU2013151301A/ru not_active Application Discontinuation
- 2012-04-20 BR BR112013027070A patent/BR112013027070A2/pt not_active IP Right Cessation
- 2012-04-20 CN CN201280029769.5A patent/CN104271740A/zh active Pending
- 2012-04-20 CA CA2871089A patent/CA2871089A1/en not_active Abandoned
- 2012-04-20 JP JP2014506610A patent/JP2014519806A/ja active Pending
- 2012-04-20 WO PCT/US2012/034595 patent/WO2012145729A2/en not_active Ceased
- 2012-04-20 US US14/113,093 patent/US20150038549A1/en not_active Abandoned
- 2012-04-20 AU AU2012245188A patent/AU2012245188A1/en not_active Abandoned
- 2012-04-20 EP EP12774523.0A patent/EP2699271A4/en not_active Withdrawn
-
2013
- 2013-10-17 IL IL228951A patent/IL228951A0/en unknown
-
2016
- 2016-04-07 US US15/093,711 patent/US20160272972A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ617944A (en) | 2016-01-29 |
| WO2012145729A3 (en) | 2014-05-01 |
| IL228951A0 (en) | 2013-12-31 |
| EP2699271A4 (en) | 2015-10-07 |
| JP2014519806A (ja) | 2014-08-21 |
| CN104271740A (zh) | 2015-01-07 |
| AU2012245188A1 (en) | 2013-12-05 |
| CA2871089A1 (en) | 2012-10-26 |
| US20150038549A1 (en) | 2015-02-05 |
| US20160272972A1 (en) | 2016-09-22 |
| WO2012145729A2 (en) | 2012-10-26 |
| EP2699271A2 (en) | 2014-02-26 |
| BR112013027070A2 (pt) | 2019-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013151301A (ru) | Способы и композиции для модулирования экспрессии генов с использованием компонентов, которые обладают способностью к самосборке в клетках и обусловливают рнкi-активность | |
| AU2009218704C1 (en) | MicroRNA (miRNA) and downstream targets for diagnostic and therapeutic purposes | |
| ES2621863T3 (es) | Compuestos de microARN y métodos para modular la actividad de miR-21 | |
| US20150225722A1 (en) | Methods for selective targeting of heterochromatin forming non-coding rna | |
| KR20160074368A (ko) | Utrn 발현을 조절하기 위한 조성물 및 방법 | |
| JP2015518712A (ja) | Ｍｅｃｐ２発現を調節するための組成物及び方法 | |
| AU2011293195A1 (en) | MiR-33 inhibitors and uses thereof | |
| CN113166760A (zh) | 用于抑制angptl8的新型rna组合物和方法 | |
| JP2013511964A (ja) | ｍｉＲＮＡ−１００を含む医薬組成物ならびに血管増殖および内皮炎症を調節するためのその使用 | |
| WO2016006697A1 (ja) | アンチセンス抗悪性腫瘍剤 | |
| JP2020202845A (ja) | 修飾抗ｍｉｒ−１３８オリゴヌクレオチド | |
| ES2990026T3 (es) | Compuestos y métodos para modular la expresión del angiotensinógeno | |
| WO2014124155A2 (en) | Methods for inducing cardiomyocyte proliferation | |
| CA3117981A1 (en) | Microrna compounds and methods for modulating mir-10b activity | |
| IL309682A (en) | products and preparations | |
| WO2022026648A1 (en) | Inhibition of incexact1 to treat heart disease | |
| JP7241098B2 (ja) | 線維症治療剤 | |
| WO2011103135A1 (en) | The use of mir-30e to treat vascular lesions | |
| KR20150140598A (ko) | 이중가닥 마이크로 rna를 유효성분으로 포함하는 암 예방용 또는 치료용 조성물 | |
| JP2025501269A (ja) | アンチセンスオリゴヌクレオチド及びその使用 | |
| EP3294887A1 (en) | Mirna compositions for the treatment of mature b-cell neoplasms | |
| Sarli | Advancing Oligonucleotide Technologies for Malignant Brain Tumors and Other Central Nervous System Diseases | |
| WO2023147400A1 (en) | Compositions and methods for inhibiting stag1 expression and uses thereof | |
| AU2014256406A1 (en) | MicroRNA (miRNA) and downstream targets for diagnostic and therapeutic purposes | |
| TWI585204B (zh) | 用以治療癌症之短干擾核糖核酸分子 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HE9A | Changing address for correspondence with an applicant | ||
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180201 |